Trade Nektar Therapeutics - NKTR CFD

Add to favourite

1.3574

8.82%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.0152

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Nektar Therapeutics ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	1.2474
Open*	1.3174
1-Year Change*	60.66%
Day's Range*	1.2874 - 1.3974
52 wk Range	0.41-3.19
Average Volume (10 days)	905.27K
Average Volume (3 months)	30.15M
Market Cap	104.92M
P/E Ratio	-100.00K
Shares Outstanding	190.77M
Revenue	88.26M
EPS	-1.55
Dividend (Yield %)	N/A
Beta	0.78
Next Earnings Date	Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 22, 2024	1.3574	0.0800	6.26%	1.2774	1.3974	1.2774
Apr 19, 2024	1.2474	-0.0500	-3.85%	1.2974	1.3174	1.1974
Apr 18, 2024	1.2874	0.0100	0.78%	1.2774	1.3474	1.2674
Apr 17, 2024	1.3374	-0.1100	-7.60%	1.4474	1.4774	1.2774
Apr 16, 2024	1.4874	0.0500	3.48%	1.4374	1.5674	1.4274
Apr 15, 2024	1.5574	-0.0700	-4.30%	1.6274	1.6874	1.4874
Apr 12, 2024	1.6574	0.1100	7.11%	1.5474	1.6674	1.4774
Apr 11, 2024	1.5674	0.1600	11.37%	1.4074	1.7374	1.4074
Apr 10, 2024	1.2974	0.1400	12.10%	1.1574	1.3774	1.1574
Apr 9, 2024	1.2574	-0.0500	-3.82%	1.3074	1.3274	1.2374
Apr 8, 2024	1.3074	-0.0300	-2.24%	1.3374	1.3874	1.2174
Apr 5, 2024	1.3174	0.0000	0.00%	1.3174	1.4574	1.2574
Apr 4, 2024	1.3274	0.2500	23.20%	1.0774	1.3774	1.0774
Apr 3, 2024	1.0474	0.1038	11.00%	0.9436	1.1174	0.9436
Apr 2, 2024	0.9572	0.0973	11.32%	0.8599	1.0074	0.8599
Apr 1, 2024	0.9033	0.0040	0.44%	0.8993	0.9340	0.8896
Mar 28, 2024	0.9074	0.0300	3.42%	0.8774	0.9189	0.8558
Mar 27, 2024	0.8651	-0.0089	-1.02%	0.8740	0.9118	0.8374
Mar 26, 2024	0.8874	-0.0067	-0.75%	0.8941	0.9106	0.8678
Mar 25, 2024	0.8916	-0.0073	-0.81%	0.8989	0.9154	0.8515

Nektar Therapeutics Events

Time (UTC)	Country	Event
Tuesday, May 7, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Nektar Therapeutics Earnings Release Q1 2024 Nektar Therapeutics Earnings Release Forecast - Previous -
Friday, June 7, 2024
Time (UTC) 21:00	Country US	Event Nektar Therapeutics Annual Shareholders Meeting Nektar Therapeutics Annual Shareholders Meeting Forecast - Previous -
Tuesday, August 6, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Nektar Therapeutics Earnings Release Q2 2024 Nektar Therapeutics Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	92.055	101.907	152.915	114.617	1193.32
Revenue	92.055	101.907	152.915	114.617	1193.32
Cost of Revenue, Total	21.635	24.897	19.477	21.374	24.412
Gross Profit	70.42	77.01	133.438	93.243	1168.91
Total Operating Expense	468.221	548.01	578.026	554.652	505.391
Selling/General/Admin. Expenses, Total	92.333	122.844	104.682	98.712	81.443
Research & Development	218.323	400.269	408.678	434.566	399.536
Unusual Expense (Income)	135.93	0	45.2	0	0
Operating Income	-376.166	-446.103	-425.111	-440.035	687.932
Interest Income (Expense), Net Non-Operating	11.183	-52.767	-18.836	-0.019	-5.207
Net Income Before Taxes	-364.983	-523.28	-443.947	-440.054	682.725
Net Income After Taxes	-368.198	-523.837	-444.44	-440.644	681.358
Net Income Before Extra. Items	-368.198	-523.837	-444.44	-440.644	681.358
Net Income	-368.198	-523.837	-444.44	-440.667	681.313
Income Available to Common Excl. Extra. Items	-368.198	-523.837	-444.44	-440.644	681.358
Income Available to Common Incl. Extra. Items	-368.198	-523.837	-444.44	-440.667	681.313
Diluted Net Income	-368.198	-523.837	-444.44	-440.667	681.313
Diluted Weighted Average Shares	187.138	183.298	178.581	174.993	180.119
Diluted EPS Excluding Extraordinary Items	-1.96752	-2.85784	-2.48873	-2.51807	3.78282
Diluted Normalized EPS	-1.49539	-2.85784	-2.32421	-2.51807	3.78282
Total Extraordinary Items				-0.023	-0.045
Other Operating Expenses, Total			-0.011
Other, Net	0	-24.41

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	20.499	21.594	22.023	23.625	21.585
Revenue	20.499	21.594	22.023	23.625	21.585
Cost of Revenue, Total	6.994	7.06	6.233	4.972	5.115
Gross Profit	13.505	14.534	15.79	18.653	16.47
Total Operating Expense	71.098	156.304	74.492	77.926	174.421
Selling/General/Admin. Expenses, Total	17.869	21.081	21.939	22.534	20.521
Research & Development	29.681	30.469	34.74	33.59	42.74
Unusual Expense (Income)	16.554	97.694	11.58	16.83	106.045
Operating Income	-50.599	-134.71	-52.469	-54.301	-152.836
Interest Income (Expense), Net Non-Operating	-0.57	-2.371	-4.075	-4.903	-6.132
Net Income Before Taxes	-51.169	-137.081	-56.544	-59.204	-158.968
Net Income After Taxes	-51.122	-137.018	-59.688	-59.049	-159.068
Net Income Before Extra. Items	-51.122	-137.018	-59.688	-59.049	-159.068
Net Income	-51.122	-137.018	-59.688	-59.049	-159.068
Income Available to Common Excl. Extra. Items	-51.122	-137.018	-59.688	-59.049	-159.068
Income Available to Common Incl. Extra. Items	-51.122	-137.018	-59.688	-59.049	-159.068
Diluted Net Income	-51.122	-137.018	-59.688	-59.049	-159.068
Diluted Weighted Average Shares	189.656	188.875	188.251	187.641	186.8
Diluted EPS Excluding Extraordinary Items	-0.26955	-0.72544	-0.31707	-0.31469	-0.85154
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.21282	-0.38924	-0.27708	-0.25639	-0.48254
Other, Net

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	545.968	795.581	1138.01	1421.55	1437.69
Cash and Short Term Investments	504.977	733.955	1061.9	1324.86	1335.35
Cash & Equivalents	88.227	25.218	198.955	96.363	194.905
Short Term Investments	416.75	708.737	862.941	1228.5	1140.44
Total Receivables, Net	5.981	22.492	38.889	36.802	43.213
Accounts Receivable - Trade, Net	5.981	22.492	38.889	36.802	43.213
Total Inventory	19.202	15.801	15.292	12.665	11.381
Other Current Assets, Total	15.808	23.333	18.02	15.387	21.293
Total Assets	710.6	1117.19	1538.77	1977.36	2150.17
Property/Plant/Equipment, Total - Net	85.886	177.535	186.138	199.176	48.851
Property/Plant/Equipment, Total - Gross	210.617	325.574	324.626	327.051	169.358
Accumulated Depreciation, Total	-124.731	-148.039	-138.488	-127.875	-120.507
Goodwill, Net	76.501	76.501	76.501	76.501	76.501
Long Term Investments	0	64.828	136.662	279.119	582.889
Other Long Term Assets, Total	2.245	2.744	1.461	1.01	4.244
Total Current Liabilities	68.204	85.2	115.779	353.893	82.002
Accounts Payable	12.98	9.747	22.139	19.234	5.854
Accrued Expenses	55.224	75.453	93.549	79.525	61.763
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total			0.091	6.441	14.385
Total Liabilities	343.962	437.681	461.472	571.965	432.597
Total Long Term Debt	0	0	0	0	246.95
Long Term Debt				0	246.95
Other Liabilities, Total	275.758	352.481	345.693	218.072	103.645
Total Equity	366.638	679.508	1077.3	1405.39	1717.57
Common Stock	0.019	0.019	0.018	0.017	0.017
Additional Paid-In Capital	3574.72	3516.64	3388.73	3271.1	3147.93
Retained Earnings (Accumulated Deficit)	-3201.19	-2833	-2309.16	-1864.72	-1424.05
Other Equity, Total	-6.907	-4.157	-2.295	-1.005	-6.316
Total Liabilities & Shareholders’ Equity	710.6	1117.19	1538.77	1977.36	2150.17
Total Common Shares Outstanding	188.56	185.468	180.091	176.505	173.53
Prepaid Expenses			3.908	31.834	26.45
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Current Port. of LT Debt/Capital Leases			0	248.693

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	399.025	441.058	491.066	545.968	599.483
Cash and Short Term Investments	372.658	409.432	456.827	504.977	546.387
Cash & Equivalents	64.921	50.728	76.955	88.227	105.758
Short Term Investments	307.737	358.704	379.872	416.75	440.629
Total Receivables, Net	2.204	1.335	2.995	5.981	11.532
Accounts Receivable - Trade, Net	2.204	1.335	2.995	5.981	11.532
Total Inventory	15.13	20.689	20.235	19.202	19.057
Other Current Assets, Total	9.033	9.602	11.009	15.808	22.507
Total Assets	442.244	494.279	561.743	710.6	781.006
Property/Plant/Equipment, Total - Net	38.696	51.569	69.271	85.886	102.699
Goodwill, Net	0	0	0	76.501	76.501
Long Term Investments				0	0
Other Long Term Assets, Total	4.523	1.652	1.406	2.245	2.323
Total Current Liabilities	52.112	50.694	59.879	68.204	83.989
Accounts Payable	3.288	2.619	3.696	12.98	5.329
Accrued Expenses	48.824	48.075	56.183	55.224	78.66
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	282.876	297.321	320.878	343.962	368.783
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	230.764	246.627	260.999	275.758	284.794
Total Equity	159.368	196.958	240.865	366.638	412.223
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	0.019	0.019	0.019	0.019	0.019
Additional Paid-In Capital	3600.87	3592.72	3584.74	3574.72	3561.88
Retained Earnings (Accumulated Deficit)	-3435.17	-3389.33	-3338.21	-3201.19	-3141.5
Other Equity, Total	-6.352	-6.45	-5.681	-6.907	-8.169
Total Liabilities & Shareholders’ Equity	442.244	494.279	561.743	710.6	781.006
Total Common Shares Outstanding	190.771	190.119	189.235	188.56	187.954
Property/Plant/Equipment, Total - Gross	126.939	159.206	179.924	210.617	237.763
Accumulated Depreciation, Total	-88.243	-107.637	-110.653	-124.731	-135.064

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-368.198	-523.837	-444.44	-440.667	681.313
Cash From Operating Activities	-304.007	-412.66	-313.287	-328.681	718.214
Cash From Operating Activities	13.03	14.146	14.182	13.156	10.87
Non-Cash Items	47.961	120.107	100.259	77.142	65.037
Cash Taxes Paid	0.272	0.325	0.539	0.555	0.618
Cash Interest Paid	0	0	9.742	19.199	19.471
Changes in Working Capital	0.492	-23.076	16.712	21.688	-39.006
Cash From Investing Activities	365.835	202.777	496.213	206.886	-1379.94
Capital Expenditures	-5.676	-14.989	-7.258	-26.285	-14.239
Other Investing Cash Flow Items, Total	371.511	217.766	503.471	233.171	-1365.7
Cash From Financing Activities	1.508	36.238	-80.354	23.355	851.966
Financing Cash Flow Items	0.75	3	146.25
Issuance (Retirement) of Stock, Net	0.758	33.238	23.396	23.355	851.966
Issuance (Retirement) of Debt, Net	0	0	-250	0	0
Foreign Exchange Effects	-0.327	-0.092	0.02	-0.102	-0.101
Net Change in Cash	63.009	-173.737	102.592	-98.542	190.143
Deferred Taxes	2.708

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-137.018	-368.198	-308.51	-249.461	-90.393
Cash From Operating Activities	-51.915	-304.007	-246.304	-163.417	-88.424
Cash From Operating Activities	2.302	13.03	9.848	7.171	3.73
Non-Cash Items	86.135	47.961	43.798	42.541	-16.271
Cash Interest Paid					0
Changes in Working Capital	-1.522	0.492	8.56	36.332	14.51
Cash From Investing Activities	40.598	365.835	325.821	214.426	130.278
Capital Expenditures	-0.433	-5.676	-5.164	-4.983	-4.203
Other Investing Cash Flow Items, Total	41.031	371.511	330.985	219.409	134.481
Cash From Financing Activities	0	1.508	1.405	1.405	0.938
Financing Cash Flow Items	0	0.75	0.75	0.75	0.75
Issuance (Retirement) of Stock, Net	0	0.758	0.655	0.655	0.188
Foreign Exchange Effects	0.045	-0.327	-0.382	-0.087	-0.017
Net Change in Cash	-11.272	63.009	80.54	52.327	42.775
Issuance (Retirement) of Debt, Net		0
Deferred Taxes	-1.812	2.708

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Nektar Company profile

About Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Nektar Therapeutics revenues decreased 33% to $101.9M. Net loss increased 18% to $523.8M. Revenues reflect United States segment decrease of 84% to $10.1M. Higher net loss reflects Non-cash interest expense on liabilities increase of 56% to $47.3M (expense), Interest income and other income (expens decrease of 86% to $2.6M (income).

Equity composition

Common Stock $.0001 Par, 04/11, 300M auth., 114,073,353 issd.Insiders own 0.39% . IPO: 5/94,2.15M shares @ $7.50 by Lehman Brothers. PO 12/97, 1.725Mshares @ $24.875 by Lehman Brothers. *NOTE: 2/97, 1.8M shsissued in private placement @ $18/shs. 8/00, 2-for-1 stock split. Sr B Conv. Pfd. $0.0001 Par, 0 o/s.

Industry:

Pharmaceuticals (NEC)

455 Mission Bay Boulevard South
SAN FRANCISCO
CALIFORNIA 94158
US

Income Statement

Annual
Quarterly

News

We’re partnering with Newsquawk

Filter out the noise and focus on the news that matters.

08:32, 23 April 2024

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024